TCGA-XF-A9T8-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.73193167
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- ALLOGRAFT_REJECTION+0.610
- INTERFERON_GAMMA_RESPONSE+0.590
- INFLAMMATORY_RESPONSE+0.560
- TNFA_SIGNALING_VIA_NFKB+0.540
- IL6_JAK_STAT3_SIGNALING+0.490
- COMPLEMENT+0.460
- G2M_CHECKPOINT+0.460
- MTORC1_SIGNALING+0.450
- E2F_TARGETS+0.440
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.210
- BILE_ACID_METABOLISM-0.170
- KRAS_SIGNALING_DN-0.110
- SPERMATOGENESIS-0.070
- WNT_BETA_CATENIN_SIGNALING-0.040
- XENOBIOTIC_METABOLISM-0.030
- PROTEIN_SECRETION+0.010
- FATTY_ACID_METABOLISM+0.020
- ESTROGEN_RESPONSE_EARLY+0.040
- MYOGENESIS+0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013494 | — | cohortA1 | 0.935 |
| 2 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.934 |
| 3 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.934 |
| 4 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.933 |
| 5 | SRR934903 | — | — | 0.930 |
| 6 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.929 |
| 7 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.929 |
| 8 | SRR934722 | — | — | 0.928 |
| 9 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.927 |
| 10 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.610 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.430 | Idelalisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |